Archives
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
br STAR Methods br Author Contributions br Acknowledgments W
2024-06-19

STAR★Methods Author Contributions Acknowledgments We thank Craig D. Wenger and Neva C. Durand for helpful advice, guidance, and discussions. D.H.P. is supported by the NIH National Human Genome Research Institute (NHGRI) (grant R00HG008662) and the Damon Runyon Cancer Research Foundation (D
-
br Methods for antifungal testing of mucorales
2024-06-19

Methods for antifungal testing of mucorales species The Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) reference methods currently in place for in vitro antifungal susceptibility testing of filamentous fungi [8], [9] have
-
The current antifungal pipeline contains several categories
2024-06-19

The current antifungal pipeline contains several categories of compounds at different stages of development [1], [9], [10], [96]. In Table 1 we summarize the most promising antifungal molecules that are in preclinical and in clinical development. Several compounds in the pipeline are derivatives of
-
Although mature fibrils formed from A aggregates
2024-06-19

Although mature fibrils formed from Aβ SMIP004 mg have long been thought to be the main neurodegenerative agents in AD, recent evidence suggests that soluble multimers of these pathogenic proteins, referred to here as “oligomers,” may initiate the synaptic and neuronal dysfunction associated with AD
-
Synaptic scaling up is induced within primary
2024-06-19

Synaptic scaling up is induced within primary visual CGP 53353 sale (V1) by brief sensory deprivation (Desai et al., 2002; Lambo and Turrigiano, 2013). Several studies have examined the transcriptional changes within extracts of V1 following visual deprivation protocols (Lachance and Chaudhuri, 200
-
Analysis of the crystal structures of LAPs from
2024-06-19

Analysis of the crystal structures of LAPs from E. coli[29], bovine eye lens [30], Pseudomonas putida[27], tomato [31] and P. falciparum[32] revealed that the monomer of M17-family LAP is composed of two domains: the smaller, variable N-terminal domain and the larger, conserved C-terminal domain tha
-
In pancreatic islets we found
2024-06-19

In pancreatic islets we found an increase in protein expression of leukocyte 12/15-LO that paralleled the metabolic decline characterized by severe hyperglycemia and reduced islet numbers. Similar increase in 12/15-LO expression by Western blot was found in the control mice, which have a normal meta
-
CEP-18770 synthesis For hippocampal asymmetry two SNPs rs
2024-06-19

For hippocampal asymmetry, two SNPs (rs1476679 and rs4147929) showed significant interaction with diagnosis. They have an inverse effect on asymmetry, which is consistent with their different roles as preventative or risk loci in AD. rs1476679 is intronic in the ZCWPW1 gene, is a histone modificatio
-
When a clinician diagnoses a person with
2024-06-19

When a clinician diagnoses a person with AD, the person is transformed into a patient with the disease. The person is a member of a patient group associated with behaviors, abilities, and experiences related both formally and informally to the diagnosis [10]. The diagnostic label implies what signs
-
Notably we have characterized the mechanism of
2024-06-19

Notably, we have characterized the mechanism of action of ALK in the context of our current understanding of NLRP3 activation [5]. Non-priming macrophages, including BMDMs, exhibit no or minimal activation of NLRP3 in response to ATP. In contrast, LPS priming of macrophages makes them highly suscept
-
Notably we have characterized the mechanism of
2024-06-19

Notably, we have characterized the mechanism of action of ALK in the context of our current understanding of NLRP3 activation [5]. Non-priming macrophages, including BMDMs, exhibit no or minimal activation of NLRP3 in response to ATP. In contrast, LPS priming of macrophages makes them highly suscept
-
We now present a series of findings obtained
2024-06-19

We now present a series of findings obtained in heterologous expression systems, brain slices, and living animals that suggest that any interaction between mGlu7 and α1-adrenergic receptors exists, is specific, and is physiologically and behaviourally relevant. Materials and methods Norepinephri
-
Epithelial mesenchymal transition EMT is the
2024-06-19

Epithelial-mesenchymal transition (EMT) is the process by which epithelial cells are trans-differentiated into motile mesenchymal cells. During EMT, epithelial cells reorganize their cortical ASP015K cytoskeleton, lose their junctions and apical-basal polarity, change cell shape, and reprogram gene
-
The obtained results indicate that even when the impairment
2024-06-19

The obtained results indicate that even when the impairment of the same forms of memory are present, amnesia can develop in different ways. Impairment of memory reconsolidation in the conditioned food aversion model through both the serotonin receptor antagonist and the antagonist of NMDA glutamate
-
br Expression of autotaxin in cancer Autotaxin ATX
2024-06-18

Expression of autotaxin in cancer Autotaxin (ATX) is a member of the family of NPPs (Nucleotides pyrophosphatases phosphodiesterases (NPP) family with a unique lysophospholipase D (lysoPLD) activity, allowing the synthesis of LPA from lysophospholipid precursors such as the lysophosphatidylcholin
16297 records 140/1087 page Previous Next First page 上5页 136137138139140 下5页 Last page